Skip to content

US · AMPH · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Amphastar Pharmaceuticals, Inc. (AMPH) intrinsic value and stock valuation

$28.25as of 2026-11-21 · Mkt cap 892.44M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Amphastar Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values AMPH with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from AMPH’s statements →

Amphastar Pharmaceuticals, Inc. Graham Number

Graham Number: $28.23d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Rancho Cucamonga, CA 91730 amphastar.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$719.9M+15.5% 5y CAGRd
20112025
Net income
$98.1M+133.9% 5y CAGRd
20112025
Free cash flow
$121.2M+38.9% 5y CAGRd
20112025
Total equity
$788.8M+11.9% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$719.9M$732M$644.4M$499M$437.8M
Operating income$140.4M$205.4M$197M$107.5M$69.9M
Net income$98.1M$159.5M$137.5M$91.4M$62.1M
EPSd$2.03M$3.06M$2.6M$1.74M$1.25M
Operating cash flow$156.1M$213.4M$183.5M$89.2M$98M
Capital expenditure-$-34.88M-$-41.04M-$-38.17M-$-24.03M-$-27.46M
Free cash flow$121.2M$172.3M$145.3M$65.2M$70.5M
Total assets$1.63B$1.58B$1.51B$742M$671.5M
Total debt$656M$650.6M$623.6M$102.6M$104.7M
Net debt$485.8M$498.9M$479.4M-$-53.52M-$-21.69M
Total equity$788.8M$732.3M$639.4M$528.7M$445.5M
Cash and short-term investments$282.8M$221.7M$256.8M$175.8M$136.7M
Income statement
20252024202320222021
Revenue$719.9M$732M$644.4M$499M$437.8M
Cost of revenue$363.8M$358.1M$293.3M$250.1M$238M
Gross profit$356.1M$373.9M$351.1M$248.9M$199.7M
Research and development expenses$85.8M$73.9M$73.7M$74.8M$60.9M
Selling, general and administrative expenses$129.8M$94.5M$80.4M$66.6M$68.9M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$215.7M$168.4M$154.1M$141.4M$129.9M
Cost and expenses$579.5M$526.6M$447.4M$391.5M$367.9M
Interest income$8.68M$10.6M$5.46M$1.32M$600K
Interest expense$25.5M$30.3M$27.2M$1.85M$890K
Depreciation and amortization$63.2M$57.2M$41.8M$28.3M$26.5M
Ebitda$212.3M$277.3M$240.3M$146.2M$111.6M
Operating income$140.4M$205.4M$197M$107.5M$69.9M
Total other income/expenses, net-$-16.78M-$-16.23M-$-27.61M$7.37M$14M
Income before tax$123.6M$189.2M$169.4M$114.9M$83.9M
Income tax expense$25.5M$29.7M$31.8M$23.5M$20.6M
Net income$98.1M$159.5M$137.5M$91.4M$62.1M
Weighted average shares outstanding$46.7M$48.4M$48.3M$48.6M$47.8M
Weighted average diluted shares outstanding$48.2M$52.1M$53M$52.4M$49.8M
Balance sheet
20252024202320222021
Cash and short-term investments$282.8M$221.7M$256.8M$175.8M$136.7M
Net receivables$143.6M$138M$115.5M$88.8M$78.8M
Inventory$176.9M$153.7M$105.8M$103.6M$92.8M
Total current assets$636M$534.1M$489.6M$378.3M$318.1M
Property, plant and equipment, net$353.7M$344.6M$315.6M$264.6M$271.5M
Goodwill and intangible assets$566M$590.7M$613.3M$37.3M$38.9M
Long-term investments$0.00$11M$15.2M$2.41M$3.98M
Total non-current assets$993.3M$1.04B$1.02B$363.7M$353.4M
Total assets$1.63B$1.58B$1.51B$742M$671.5M
Accounts payable$32.6M$30.5M$25.4M$20.5M$22.2M
Short-term debt$9.57M$7.04M$4.34M$6.05M$5.18M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$158.2M$173.8M$225.4M$94.9M$103.8M
Long-term debt$646.4M$643.5M$619.3M$96.5M$99.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$682.3M$671.4M$648.1M$118.5M$122.2M
Capital lease obligations$45.7M$48.7M$33.6M$26.7M$28.1M
Total liabilities$840.5M$845.2M$873.5M$213.3M$226M
Common stock$10K$10K$10K$10K$10K
Retained earnings$666.9M$568.8M$409.3M$271.7M$180.3M
Accumulated other comprehensive income (loss)-$-5.31M-$-9.18M-$-8.48M-$-8.62M-$-6.76M
Total equity$788.8M$732.3M$639.4M$528.7M$445.5M
Total investments$112.6M$81M$127.7M$22.1M$14.3M
Total debt$656M$650.6M$623.6M$102.6M$104.7M
Net debt$485.8M$498.9M$479.4M-$-53.52M-$-21.69M
Cash flow statement
20252024202320222021
Net income$98.1M$159.5M$137.5M$91.4M$63.3M
Depreciation and amortization$63.2M$57.2M$41.8M$28.7M$26.8M
Stock-based compensation$27.3M$24.4M$20.2M$17.9M$18.7M
Change in working capital-$-65.97M-$-14.55M-$-24.21M-$-32.18M-$-1.92M
Accounts receivable-$-6.37M-$-21.67M-$-26.09M-$-10.13M-$-14.92M
Inventory-$-21.06M-$-48.8M-$-1.72M-$-11.75M$1.26M
Accounts payable-$-4.56M$63.6M$13.2M-$-740K$3.02M
Net cash provided by operating activities$156.1M$213.4M$183.5M$89.2M$98M
Investments in property, plant and equipment-$-34.88M-$-41.04M-$-38.17M-$-24.03M-$-27.46M
Acquisitions, net$0.00-$-129M-$-506.41M$420K$0.00
Net cash used for investing activities-$-70.33M-$-124.93M-$-649.12M-$-32.78M-$-28.67M
Common stock issued$2.85M$0.00$0.00$0.00$0.00
Common stock repurchased-$-75.59M-$-85.46M-$-58.14M-$-39.91M-$-28.87M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-67.42M-$-80.95M$454.1M-$-26.44M-$-37.02M
Net change in cash$18.6M$7.31M-$-11.8M$29.8M$32.1M
Cash at end of period$170.4M$151.8M$144.5M$156.3M$126.6M
Operating cash flow$156.1M$213.4M$183.5M$89.2M$98M
Capital expenditure-$-34.88M-$-41.04M-$-38.17M-$-24.03M-$-27.46M
Free cash flow$121.2M$172.3M$145.3M$65.2M$70.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Amphastar Pharmaceuticals, Inc.

        Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

        CEO
        Yongfeng Zhang
        Employees
        1.98K
        Beta
        0.89

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Amphastar Pharmaceuticals, Inc. (AMPH)?

        Amphastar Pharmaceuticals, Inc. (AMPH) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AMPH undervalued?

        AMPH trades at a price of $28.25 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.